HRP conjugated Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A) . Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL) . HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

Product Specifications

Background

CAS Number

9007-83-4

Host

HEK293

Origin Species

Mouse

Target

DXD

Conjugation

HRP Labeled

Tag

Mouse IgG1 | Mouse kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please protect from light and avoid repeated freeze-thaw cycles.

Purity

90%

Bioactivity

Immobilized Trastuzumab-Exatcan at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-PLM684) with a linear range of 1-16 ng/mL (Routinely tested).